| First Author | Priel E | Year | 1993 |
| Journal | J Virol | Volume | 67 |
| Issue | 6 | Pages | 3624-9 |
| PubMed ID | 8388515 | Mgi Jnum | J:4979 |
| Mgi Id | MGI:53458 | Doi | 10.1128/jvi.67.6.3624-3629.1993 |
| Citation | Priel E, et al. (1993) Inhibition of retrovirus-induced disease in mice by camptothecin. J Virol 67(6):3624-9 |
| abstractText | We have previously shown that noncytotoxic doses of camptothecin (CPT), a topoisomerase I-specific antagonist, inhibit retrovirus replication in acutely and chronically infected cells. To evaluate the efficacy of CPT as an antiretroviral drug in vivo, we injected newborn BALB/c mice with Moloney murine leukemia virus and adult NFS mice with Friend spleen focus-forming virus. The Moloney murine leukemia virus-injected mice developed lymphoma, and the Friend spleen focus-forming virus-injected mice developed erythroleukemia. CPT, administrated together with the virus or 1 or 2 days after virus injection, prevented the onset of the disease in both cases. We showed that repeated CPT treatments increased the effectiveness of the drug when administrated 3 days after virus injection. This ability of CPT to inhibit retrovirus-induced disease in vivo without causing any apparent toxic side effects suggests its application as a legitimate remedy for the treatment of retroviral diseases. |
